“Alzheimer’s: Rethinking the ‘One-Size-Fits-All’ Approach,” by Judy George, MedPage Today
“Precision medicine in Alzheimer’s disease — tailoring prevention and treatment to a patient’s unique risk profile — surfaced as a key theme at the NIH National Institute on Aging (NIA) 2018 Alzheimer’s Disease Research Summit. ‘Alzheimer’s disease is a heterogeneous disorder. We are learning more about genetic and environmental risk factors, and we need to start differentiating Alzheimer’s patients based on genetics, environmental exposure, and clinical history,’ Eliezer Masliah, MD, head of the NIA neuroscience division, told MedPage Today.’ This might be more effective than a one-size-fits-all type of approach, which is where we are right now.’”
LTC Comment (from Stephen A. Moses, Administrative Coordinator, Center for Long-Term Care Reform):
This seems like a promising direction for research to take given the dramatic failure to target drugs toward single causes.